Question special

Thank you to Dr. Pollack, co-authors, and experts for taking the time to participate in this thought provoking discussion.

On the last day of this discussion I would like to follow up from Dr. Boyer’s question on the cost of idarucizumab. What are considerations for the optimal use of idarucizumab? Should patients be tested for the degree of anticoagulation activity attributed to dabigatran to assess if idarucizumab administration is required?